Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01993862 · ClinicalTrials.gov registry record · NA

Same Day Discharge (SDD) After Implantable Cardioverter Defibrillator (ICD) Implant

A NA study of Heart Failure and Coronary Artery Disease, sponsored by Abbott Medical Devices.

Completed
Registry status
NA
Development phase
266
Enrollment target
20
Study locations

NCT01993862: Completed NA study of Heart Failure and Coronary Artery Disease, sponsored by Abbott Medical Devices.

NCT01993862 is a NA study of Heart Failure and Coronary Artery Disease that has completed, run by Abbott Medical Devices. The registered enrollment target is 266 participants, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01993862, a NA study of Heart Failure and Coronary Artery Disease, has completed, sponsored by Abbott Medical Devices.

COMPLETED
Registry status
NA
Development phase
266 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to determine whether it is safe to send patients home from the hospital on the same day following an implantable cardioverter defibrillator (ICD) implant.

Interventions

  • OTHER Same Day Discharge

Study Locations (20)

California

  • Chula Vista Cardiac Center - Chula Vista
  • Cardiovascular Consultants Heart Center - Fresno
  • Stanislaus Cardiology Group - Modesto
  • Sutter Medical Center of Santa Rosa - Santa Rosa

Florida

  • Lakeland Regional Medical Center - Lakeland
  • Watson Clinic Center - Lakeland
  • Florida Cardiovascular Specialists - Leesburg
  • Naples Heart Rhythm Specialists, PA - Naples

Alabama

  • Heart Center Research - Huntsville
  • Cardiology Associates of Mobile - Mobile

Colorado

  • Exempla Rocky Mountain Cardiovascular Associates - Broomfield
  • South Denver Cardiology Associates PC - Littleton

Illinois

  • Loyola University Medical Center - Maywood
  • Chicago Cardiology Institute - Schaumburg

Michigan

  • Thoracic Cardiovascular Healthcare Foundation - Lansing
  • Great Lakes Heart and Cascular Institute PC - Saint Joseph

Arizona

  • John C Lincoln North Mountain Hospital - Phoenix

Louisiana

  • Ochsner Medical Center - New Orleans

Trial Details

FieldValue
Enrollment Target 266 participants
Start Date 2014-03-17
Est. Completion 2016-08-12
Phase NA
Abbott Medical Devices

261 total trials

What the finished NCT01993862 record still lists

NCT01993862 is an interventional study that assigns participants to a tested intervention. The registered 266 participants enrollment target is mid-sized for trials with a published cap, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (87% lower).

The record links to 2 conditions, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which Same Day Discharge is the first listed.

NCT01993862 names 20 study sites across 10 states, led by California, Florida, Alabama.

Frequently Asked Questions

What is clinical trial NCT01993862 about?

NCT01993862 is a clinical study titled "Same Day Discharge (SDD) After Implantable Cardioverter Defibrillator (ICD) Implant". The purpose of this study is to determine whether it is safe to send patients home from the hospital on the same day following an implantable cardioverter defibrillator (ICD) implant.

What is the current status of trial NCT01993862?

This trial is currently completed. It is a NA study. The enrollment target is 266 participants. The study started on 2014-03-17. Estimated completion is 2016-08-12.

What conditions does trial NCT01993862 study?

This clinical trial studies the following conditions: Heart Failure, Coronary Artery Disease.

What interventions are being tested in trial NCT01993862?

The interventions under investigation include: Same Day Discharge (OTHER).

Who is sponsoring clinical trial NCT01993862?

This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01993862 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heart Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01993862's enrollment target sits among peer trials

266 149th of 397 higher than 249 of 397 other Heart Failure trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Heart Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05098652 · 266 participants · NA

    Coaching Dementia Caregivers to Master Care-Resistant Behavior

  • NCT06088277 · 266 participants · NA

    Texting to Reduce Human Immunodeficiency Virus (HIV) Risk

  • NCT06261814 · 266 participants · Phase 2

    Contrast Enhanced Ultrasound to Evaluate Response to Chemoembolization in Patients With Liver Tumors

  • NCT06312124 · 266 participants · NA

    A Study of Opportunistic Salpingectomy to Prevent Ovarian Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01993862, the US trial registry maintained by the National Library of Medicine. NCT01993862 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.